NEW DELHI: Bharat Biotech’s Covaxin has shown 77.8% effectiveness in phase 3 trials, also reported ANI pruning resources.
The Hyderabad-based company had previously submitted the trial information to the Subject Expert Committee (SEC) of the Indian medication regulator.
The panel has accepted the trial information.
The trials have been conducted 25,800 subjects, according to reports.
Bharat Biotech’s indigenously developed Covaxin is among the 3 vaccines currently being used in India.
Covishield, produced by AstraZeneca and fabricated locally by Serum Institute of India and also Russia’s Sputnik V would be another two vaccines administered The firm has established the vaccine from conjunction with the Indian Council of Medical Research (ICMR).
‘Bharat Biotech’s Covaxin Reveals 77.8% Efficiency in phase 3 trials’
